Technical Analysis for RENE - Reneuron Group Plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 3.38 | -2.17% | -0.08 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -2.17% | |
Stochastic Reached Oversold | Weakness | -2.17% | |
Wide Bands | Range Expansion | -2.17% | |
Oversold Stochastic | Weakness | -2.17% | |
New 52 Week Closing Low | Bearish | -0.74% |
Get a Trading Sidekick!
Reneuron Group Plc Description
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Medicine Life Sciences Cancer Branches Of Biology Clinic Earl Biology Emerging Technologies Therapy Clinical Trial Cell Therapy Therapies Stroke Stem Cells Cell Biology Disability Nanomedicine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.5 |
52 Week Low | 3.275 |
Average Volume | 410,126 |
200-Day Moving Average | 6.68 |
50-Day Moving Average | 3.97 |
20-Day Moving Average | 4.03 |
10-Day Moving Average | 3.68 |
Average True Range | 0.31 |
RSI (14) | 36.71 |
ADX | 27.43 |
+DI | 13.56 |
-DI | 25.61 |
Chandelier Exit (Long, 3 ATRs) | 4.69 |
Chandelier Exit (Short, 3 ATRs) | 4.21 |
Upper Bollinger Bands | 4.87 |
Lower Bollinger Band | 3.19 |
Percent B (%b) | 0.11 |
BandWidth | 41.53 |
MACD Line | -0.18 |
MACD Signal Line | -0.10 |
MACD Histogram | -0.0787 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.67 | ||||
Resistance 3 (R3) | 3.67 | 3.57 | 3.62 | ||
Resistance 2 (R2) | 3.57 | 3.49 | 3.57 | 3.60 | |
Resistance 1 (R1) | 3.47 | 3.45 | 3.42 | 3.47 | 3.59 |
Pivot Point | 3.37 | 3.37 | 3.35 | 3.37 | 3.37 |
Support 1 (S1) | 3.28 | 3.30 | 3.23 | 3.28 | 3.16 |
Support 2 (S2) | 3.18 | 3.25 | 3.18 | 3.15 | |
Support 3 (S3) | 3.08 | 3.18 | 3.13 | ||
Support 4 (S4) | 3.08 |